@article{38995895db2446a39c66fe9c0c1ef7b6,
title = "Recent developments and therapeutic strategies against hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.",
author = "Mark Yarchoan and Parul Agarwal and Augusto Villanueva and Shuyun Rao and Dawson, {Laura A.} and Llovet, {Josep M.} and Finn, {Richard S.} and Groopman, {John D.} and El-Serag, {Hashem B.} and Monga, {Satdarshan P.} and Wang, {Xin Wei} and Michael Karin and Schwartz, {Robert E.} and Tanabe, {Kenneth K.} and Roberts, {Lewis R.} and Gunaratne, {Preethi H.} and Allan Tsung and Brown, {Kimberly A.} and Lawrence, {Theodore S.} and Riad Salem and Singal, {Amit G.} and Kim, {Amy K.} and Atoosa Rabiee and Linda Resar and Yujin Hoshida and He, {Aiwu Ruth} and Kalpana Ghoshal and Ryan, {Patrick B.} and Jaffee, {Elizabeth M.} and Chandan Guha and Lopa Mishra and {Norman Coleman}, C. and Ahmed, {Mansoor M.}",
note = "Funding Information: M. Yarchoan is a consultant/advisory board member for Eisai and Exelixis. A. Villanueva is a consultant/advisory board member for Guide-point, Fujifilm Wako, Exact Sciences, Nucleix, NGM Pharmaceuticals, and Exelixis. J.M Llovet reports receiving a commercial research grant from Bayer Healthcare Pharmaceuticals, Eisai, Bristol Myers-Squibb, and Ipsen, and is a consultant/advisory board member for Eli Lilly, Bayer HealthCare Pharmaceuticals, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech Inc., Spring Bank Pharmaceuticals, Nucleix, Can-Fite Biopharma, Bristol Myers-Squibb, Eisai Inc., Celsion, Exelixis, Merck, Blueprint, Ipsen, and Glycotest. R.S. Finn is a consultant/advisory board member for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Pfizer, Merck, and Roche/Genentech and has given expert testimony for Novartis. S.P Monga reports receiving a commercial research grant from Dicerna and Abbvie and is a consultant/ advisory board member for Dicerna and Abbvie. L.R. Roberts reports receiving a commercial research grant from Ariad Pharmaceuticals, Bayer, Wako Diagnostics, and Exact Sciences, has received other commercial research support from Gilead Sciences, Redhill, BTG International Inc., and is a consultant/advisory board member for Bayer Pharmaceuticals, Tavec, Grail, QED, NACCME, and Wako Diagnostics. A. Tsung is a consultant/ advisory board member for Medtronic. R. Salem is a consultant/advisory board member for Eisai and BMS. A.G. Singal has received speakers bureau honoraria from BMS and Bayer, and is a consultant/advisory board member for Bayer, Eisai, BMS, Exelixis, TARGET HCC. A.K Kim consultant/advisory board member for AstraZeneca. Y. Hoshida has received commercial research support from Morphic Therapeutic, has ownership interest (including stocks and patents etc.) in Alentis Therapeutics, and is a consultant/ advisory board member for Ferring Pharmaceuticals, Kyowa Hakko Kirin, and Laboratory for Advanced Medicine. P.B. Ryan has ownership interest (including stocks and patents etc.) in Johnson & Johnson. E.M. Jaffee reports receiving a commercial research grant from BMS, AduroBiotech, and Amgen, has ownership interest (including stocks and patents etc.) in Aduro Biotech, and is a consultant/advisory board member for Dragonfly, CSTONE, and Genocea. C. Guha reports receiving a commercial research grant from Johnson & Johnson and Celldex and is a consultant/advisory board member for Varian and Johnson & Johnson. No potential conflicts of interest were disclosed by the other authors. Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",
year = "2019",
month = sep,
day = "1",
doi = "10.1158/0008-5472.CAN-19-0803",
language = "English (US)",
volume = "79",
pages = "4326--4330",
journal = "Cancer Research",
issn = "0008-5472",
number = "17",
}